{
    "clinical_study": {
        "@rank": "27013", 
        "brief_summary": {
            "textblock": "To determine the safety and efficacy of decitabine in patients with Philadelphia\n      chromosome-positive chronic myelogenous leukemia chronic phase that were previously treated\n      with imatinib mesylate (STI 571) and became resistant/refractory or were found to be\n      intolerant to the drug."
        }, 
        "brief_title": "Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Chronic Phase Who Are Refractory to Imatinib Mesylate (Gleevec)", 
        "condition": "Chronic Myelogenous Leukemia", 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Myeloid", 
                "Leukemia, Myelogenous, Chronic, BCR-ABL Positive"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion:\n\n          -  Histologically confirmed diagnosis of CML chronic phase\n\n          -  Ph chromosome-positive\n\n          -  Previous treatment with imatinib mesylate resulting in: i) Hematologic Resistance /\n             Hematologic Refractory: Based on a physician's (documented) decision to discontinue\n             imatinib mesylate treatment due to failure of continued benefit or no benefit to the\n             patient, ii) Imatinib Mesylate Intolerance: any toxicity resulting in a physician's\n             (documented) decision to discontinue imatinib mesylate treatment.\n\n          -  Patients must have recovered from the side effects of previous CML therapy for\n             chronic phase with the exception of hydroxyurea\n\n          -  Age >/= 2 years\n\n          -  Bilirubin </= 3 x the upper limit of normal (ULN), SGOT and SGPT </= 3 x ULN, except\n             </= 5 x ULN in leukemic involvement of the liver, serum creatinine </= 2 x ULN\n\n          -  WHO performance status 0-3\n\n          -  A negative serum hCG pregnancy test in patients of childbearing potential\n\n          -  Able to give signed informed consent directly or through a parent or guardian for\n             minors\n\n        Exclusion:\n\n          -  Leukemic involvement of the central nervous system\n\n          -  Active malignancy other than CML or non-melanoma cancer of the skin\n\n          -  Previous treatment for CML with another investigational agent within 28 days of study\n             entry\n\n          -  At study entry, patients who were treated with: imatinib mesylate within the past 48\n             hours; interferon-alpha within the past 48 hours; homoharringtonine within the past\n             14 days; low-dose cytosine arabinoside within 7 days, moderate dose within 14 days,\n             or high dose within 28 days; etoposide, anthracyclines, or mitoxantrone within 21\n             days; busulfan within the past six weeks\n\n          -  Patients who had received hematopoietic stem cell transplantation within 6 weeks of\n             Day 1 decitabine therapy\n\n          -  Patients with Grade 3/4 cardiac disease or any other serious concurrent medical\n             condition.\n\n          -  Patients who are pregnant or nursing. All patients of childbearing potential must\n             practice effective methods of contraception while on study.\n\n          -  Patients with mental illness or other condition precluding their ability to give\n             informed consent or to comply with study requirements\n\n          -  Patients with systemic, uncontrolled infections"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "2 Years"
        }, 
        "enrollment": "40", 
        "firstreceived_date": "July 19, 2002", 
        "id_info": {
            "nct_id": "NCT00042016", 
            "org_study_id": "DAC-014", 
            "secondary_id": "DACO-014"
        }, 
        "intervention": {
            "intervention_name": "decitabine (5-aza-2'deoxycytidine)", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Azacitidine", 
                "Decitabine", 
                "Imatinib"
            ]
        }, 
        "keyword": [
            "Chronic myelogenous leukemia", 
            "CML", 
            "CML-CP", 
            "Chronic phase", 
            "Decitabine", 
            "5-aza-2'deoxycytidine", 
            "Methylation", 
            "STI 571", 
            "Imatinib mesylate", 
            "Gleevec", 
            "BCR/ABL"
        ], 
        "lastchanged_date": "October 12, 2009", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Duarte", 
                        "country": "United States", 
                        "state": "California"
                    }, 
                    "name": "City of Hope Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Escondido", 
                        "country": "United States", 
                        "state": "California"
                    }, 
                    "name": "Scripps Clinic"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California"
                    }, 
                    "name": "USC/Norris Cancer Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St. Louis Park", 
                        "country": "United States", 
                        "state": "Minnesota"
                    }, 
                    "name": "Metro-Minnesota CCOP"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Valhalla", 
                        "country": "United States", 
                        "state": "New York"
                    }, 
                    "name": "New York Medical College"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Columbia", 
                        "country": "United States", 
                        "state": "South Carolina"
                    }, 
                    "name": "Liberty Hematology/Oncology"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77030"
                    }, 
                    "name": "University of Texas MD Anderson Cancer Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toronto", 
                        "country": "Canada", 
                        "state": "Ontario"
                    }, 
                    "name": "Princess Margaret Hospital"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Canada"
            ]
        }, 
        "official_title": "A Phase II, Multicenter Study of Decitabine (5-aza-2'Deoxycytidine) in Chronic Myelogenous Leukemia Chronic Phase Refractory to Imatinib Mesylate (STI 571)", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00042016"
        }, 
        "source": "Astex Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Astex Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2002", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2005"
    }, 
    "geocoordinates": {
        "City of Hope Medical Center": "34.139 -117.977", 
        "Liberty Hematology/Oncology": "34.001 -81.035", 
        "Metro-Minnesota CCOP": "44.96 -93.37", 
        "New York Medical College": "41.075 -73.775", 
        "Princess Margaret Hospital": "43.653 -79.383", 
        "Scripps Clinic": "33.119 -117.086", 
        "USC/Norris Cancer Center": "34.052 -118.244", 
        "University of Texas MD Anderson Cancer Center": "29.76 -95.369"
    }
}